622 completed. 622 Phase 3, 47 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 622 | Completed 622 |
| Phase 2 | 47 | Completed 47 |
Follow Bronchial Diseases: new trials by email Literature Review of Bronchial Diseases trials Research Report on Bronchial Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis YHP2401, YHR2402, YHR2403 - Acute Bronchitis | Phase 3 | Completed | Yuhan Corporation | 286 | 2025-08-19 | 2026-02-09 |
| Hyaluronic Acid Mouthwash as Adjunct Hyaluoric acid mouthwash, Chlorhexidine 0,12% - Gingivitis; Chronic | Phase 3 | Completed | Cairo University | 16 | 2025-02-01 | 2026-01-26 |
| A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA - Asthma | Phase 3 | Completed | AstraZeneca | 424 | 2024-07-22 | 2026-09-08 |
| A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma Salbutamol HFA-134a, Salbutamol HFA-152a - Asthma | Phase 3 | Completed | GlaxoSmithKline | 471 | 2024-05-31 | 2026-10-06 |
| A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212 DW5121, DW51211, DW51212 - Acute Bronchitis | Phase 3 | Completed | Daewon Pharmaceutical Co., Ltd. | 273 | 2024-03-28 | 2025-07-30 |
| Budesonide/Formoterol Inhalation Powder in Adults With Asthma Budesonide and Formoterol Fumarate, Placebo of Budesonide and Formoterol Fumarate - Asthma | Phase 3 | Completed | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | 338 | 2024-02-21 | 2026-08-27 |
| Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma Magnesium Sulphate infusion, Terbutaline Infusion - Acute Exacerbation of Asthma | Phase 3 | Completed | Muhammad Aamir Latif | 120 | 2024-01-01 | 2024-10-04 |
| A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma Budesonide/albuterol metered-dose inhaler 160/180 μg, Placebo metered-dose inhaler - Asthma, Exercise-Induced | Phase 3 | Completed | AstraZeneca | 64 | 2023-12-22 | 2025-08-27 |
| BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 - Bronchial Asthma | Phase 3 | Completed | Cipla Ltd. | 120 | 2023-12-06 | 2025-07-16 |
| Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS). CHF5993 200/6/12.5 μg pMDI HFA-152a, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a - Asthma | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 827 | 2023-11-27 | 2026-09-10 |
| Poly-unsaturated Fats for Improving Nasal Polyps and Asthma Fish oil, Placebo - Asthma | Phase 3 | Completed | Norfolk and Norwich University Hospitals NHS Foundation Trust | 18 | 2023-10-09 | 2026-06-08 |
| Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma HFA MDI, HFO MDI - Asthma | Phase 3 | Completed | AstraZeneca | 52 | 2023-05-02 | 2026-02-06 |
| Efficacy of Vitamin D Supplementation for Children With Bronchiolitis Vitamin D3 - Bronchiolitis | Phase 2 / Phase 3 | Completed | Sohag University | 146 | 2023-04-01 | 2024-10-29 |
| REVErsing Airway Remodelling With Tezepelumab Tezepelumab, placebo - Airway Remodelling, Asthmatic | Phase 3 | Completed | University Hospital, Montpellier | 90 | 2023-03-27 | 2026-07-09 |
| A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS) BFF MDI 160/9.6 μg BID (320/19.2μg/day), BD MDI 160 μg BID (320 μg/day) - Asthma | Phase 3 | Completed | AstraZeneca | 374 | 2023-02-27 | 2026-01-28 |
| Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma Tezepelumab, Placebo - Asthma | Phase 3 | Completed | McMaster University | 27 | 2022-11-08 | 2026-01-07 |
| PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction PT027, PT007 - Asthma | Phase 3 | Completed | AstraZeneca | 190 | 2022-09-28 | 2026-01-27 |
| A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma BDA MDI, AS MDI - Asthma | Phase 3 | Completed | Bond Avillion 2 Development LP | 2516 | 2022-09-02 | 2025-08-03 |
| A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid Beclomethasone Dipropionate/Formoterol Fumarate, Beclomethasone Dipropionate - Asthma | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 1377 | 2022-08-31 | 2026-07-20 |
| Nebulised 3% Hypertonic Saline in Infants With Acute Bronchiolitis 3% Sodium Chloride, Standard care - Acute Bronchiolitis | Phase 2 / Phase 3 | Completed | Can Tho University of Medicine and Pharmacy | 140 | 2022-06-01 | 2024-08-16 |
Showing 20 of 622. Sign in to see all of them.
Asthma (473) · Bronchiolitis Obliterans Syndrome (55) · Pulmonary Disease, Chronic Obstructive (33) · Bronchitis, Chronic (27) · Lung Diseases (27) · Bronchiolitis (24) · Bronchitis (21) · Respiratory Tract Diseases (20) · Lung Diseases, Obstructive (19) · Bronchiectasis (15) · Emphysema (15) · Dyspnea (9) · Asthma, Exercise-Induced (8) · Hypersensitivity (8)
Respiratory Tract Diseases (602) · Lung Diseases, Obstructive (580) · Lung Diseases (575) · Immune System Diseases (535) · Hypersensitivity, Immediate (482) · Respiratory Hypersensitivity (478) · Hypersensitivity (476) · Pathological Conditions, Signs and Symptoms (112) · Bronchitis (104) · Infections (84) · Respiratory Tract Infections (65) · Pathologic Processes (64) · Bronchiolitis (61) · Disease Attributes (55)
Budesonide (62) · Fluticasone (47) · Formoterol Fumarate (46) · Budesonide, Formoterol Fumarate Drug Combination (43) · Albuterol (37) · montelukast (35) · Salmeterol Xinafoate (29) · Beclomethasone (26) · ciclesonide (25) · Fluticasone-Salmeterol Drug Combination (19) · Omalizumab (19) · benralizumab (17) · fluticasone furoate (17) · Azithromycin (12) · Mometasone Furoate (11)
AstraZeneca (117) · GlaxoSmithKline (56) · Organon and Co (36) · Novartis Pharmaceuticals (23) · Teva Branded Pharmaceutical Products R&D, Inc. (21) · Chiesi Farmaceutici S.p.A. (20) · Milton S. Hershey Medical Center (16) · Boehringer Ingelheim (15) · Sanofi (15) · Sumitomo Pharma America, Inc. (13) · Pfizer (12) · Novartis (7) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6) · McMaster University (6) · Mundipharma Research Limited (6)
United States (270) · Germany (127) · Canada (117) · Poland (109) · Russia (84) · United Kingdom (84) · Spain (81) · France (78) · Hungary (75) · Argentina (69) · Italy (67) · Japan (67) · Ukraine (67) · Australia (65) · South Korea (59)
Catherine Bonuccelli (11) · Esther Garcia, MD (7) · Elliot Israel, MD (6) · David T. Mauger, PhD (4)
PMID 36472162, PMID 27881132, PMID 31319851, PMID 29174062, PMID 30954640, PMID 32180164, PMID 32816215, PMID 22329608, PMID 24966061, PMID 26369589, PMID 26498386, PMID 26612545, PMID 26704701, PMID 30802500, PMID 31047111, PMID 31251094, PMID 31447130, PMID 31760132, PMID 33217063, PMID 33223095, PMID 34098955, PMID 35287231, PMID 35636689, PMID 36356712, PMID 36702146, PMID 19995138, PMID 20075384, PMID 20835586, PMID 22938706, PMID 24314123, PMID 25154045, PMID 25682232, PMID 26149717, PMID 26233481, PMID 27087007, PMID 27216137, PMID 27616196, PMID 27912982, PMID 28069068, PMID 28396102, PMID 28495619, PMID 28558833, PMID 28624608, PMID 29409951, PMID 29536781, PMID 29949045, PMID 30077185, PMID 30139780, PMID 31112385, PMID 31507641
2015 (13), 2016 (11), 2009 (7), 2014 (7), 2017 (7), U10HL098115 (7), 2018 (5), 2023 (5), 2008 (4), U10HL074073 (4), U10HL074204 (4), U10HL074208 (4), U10HL074212 (4), U10HL074218 (4), U10HL074225 (4)